Exact Sciences’ Stool DNA Screening Technology Featured in Posters at Digestive Disease Week 2015

WASHINGTON-- Exact Sciences Corp. (NASDAQ: EXAS) today announced that data supporting its stool DNA (sDNA) screening platform for colorectal cancer and other screening techniques for the detection of additional gastrointestinal cancers and diseases will be presented in five posters at Digestive Disease Week (DDW) 2015, taking place May 16-19 in Washington D.C. Recently approved by the U.S. Food and Drug Administration (FDA), Exact Sciences' noninvasive screening test Cologuard® uses sDNA technology to help detect the presence of colorectal cancer and precancer. Exact Sciences' technologies can be seen at the show at booth #1552.

Read More

Topics: Exact Sciences News

Exact Sciences Reports Strong Growth Trajectory for Cologuard in First-Quarter 2015

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS) today announced its business and financial results for the quarter ending March 31, 2015, reporting that 11,000 Cologuard tests were completed and that the number of ordering physicians more than doubled, increasing from 4,100 at the end of 2014 to 8,300 in the first quarter of 2015.

Read More

Topics: Exact Sciences News

Exact Sciences and Ironwood Pharmaceuticals Enter Co-Promotion Agreement for Cologuard®

MADISON, Wis., & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today an agreement to co-promote Exact Sciences' Cologuard®, the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. The agreement provides for the near-term expansion of Cologuard promotional efforts through the use of Ironwood's clinical sales specialists to more than double the number of physicians reached in the United States. The non-exclusive co-promotion agreement covers an initial one-year term with the opportunity for extension.

Read More

Topics: Exact Sciences News